These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18675446)

  • 1. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
    Garcia AA; Blessing JA; Nolte S; Mannel RS;
    Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Garcia AA; Blessing JA; Vaccarello L; Roman LD;
    Am J Clin Oncol; 2007 Aug; 30(4):428-31. PubMed ID: 17762444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
    Pearl ML; Johnston CM; McMeekin DS
    Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
    Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
    Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.
    Günthert AR; Ackermann S; Beckmann MW; Camara O; Kiesel L; Rensing K; Schröder W; Steiner E; Emons G;
    Gynecol Oncol; 2007 Jan; 104(1):86-90. PubMed ID: 16996111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
    Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
    Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
    Grendys EC; Blessing JA; Burger R; Hoffman J
    Gynecol Oncol; 2005 Aug; 98(2):249-53. PubMed ID: 15978659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
    Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
    Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
    Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
    Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
    Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
    Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
    Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
    Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
    Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
    Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
    Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
    Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
    Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
    Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.